These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New black box warning for ritonavir-boosted tipranavir. Ryan CT AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669 [No Abstract] [Full Text] [Related]
5. Aptivus capsules granted full FDA approval. AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430 [No Abstract] [Full Text] [Related]
6. Aptivus in the hotseat. Excerpts from the FDA hearings. Huff B GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577 [No Abstract] [Full Text] [Related]
7. Tipranavir: new drug. HIV protease inhibitor. A last resort. Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925 [TBL] [Abstract][Full Text] [Related]
8. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection]. Soler-Palacín P; Fàbrega A; María López R; Figueras C Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645 [No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Unexpected results from a tipranavir study. TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836 [No Abstract] [Full Text] [Related]
10. [Desensitization to tipranavir caused by toxicodermia]. Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397 [No Abstract] [Full Text] [Related]
11. FDA approval: tipranavir. Sax PE AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574 [No Abstract] [Full Text] [Related]
12. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479 [TBL] [Abstract][Full Text] [Related]
13. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H; Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833 [TBL] [Abstract][Full Text] [Related]
14. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]